


Stabilis



Aztreonam



鋸喙搥錫

Azactam	涓涓害, 鋸(二). 鋸 鋸勤攪澶�氫毆, 鋸ヤ鸡姣旆簞, 澶×タ鋸 濂ユ逆錄 甯岌扉, 鋸忸え錄 鋸 e ■, 鋸拌 タ飽 鋸ユ滄, 姣旆烽鋸 娉曠涑, 娉(-)馭, 婢冲え錄十簞, 鋸卞毆鋸 鋸烱吁, 鋸烱+, 緹衣涑, 鋸 馭, 鋸卞 涑, 鋸峰馭, 鋸×忸鋸 瑗跨衒鋸 闐旆伋閭
Barex	浼娉澶, 闐跨牴寤
Causton	涓涓害, 鋸孀綏鋸頒簞, 鋸猗燈澶 寰峰涑, 姣旆烽鋸 鋸烱+, 緹衣涑, 瑗跨衒鋸
Monobac	澶×タ鋸
Treonam	纒檻壘
Vibactam	纒檻壘



婧舵恫緋冲晶鎢

		2 mg/ml	2-8掬C		7			4922
		60 mg/ml	-20掬C		28			1064
		60 mg/ml	4掬C		8			1064
		20 mg/ml	25掬C		48			432
		20 mg/ml	25掬C		48			432
		2 mg/ml	2-8掬C		7			4922
		60 mg/ml	-20掬C		180			1064
		60 mg/ml	37掬C		24			1064
		60 mg/ml	4掬C		70			1064
		10 mg/ml	24掬C		4			258
		10 mg/ml	5掬C		4			258
		10 & 20 mg/ml	25掬C		48			422

PVC		10 & 20 mg/ml	4掬C		7			422
PVC		20 mg/ml	-20掬C		120			1233
PVC		20 mg/ml	4掬C		120			1233
PVC		10 & 20 mg/ml	25掬C		48			422
PVC		10 & 20 mg/ml	4掬C		7			422
PVC		0,5 mg/ml	25掬C		14			4456
PVC		0,5 mg/ml	37掬C		1			4456
PVC		0,5 mg/ml	6掬C		14			4456
PVC		0,4 mg/ml	25掬C		3			4456
PVC		0,4 mg/ml	37掬C		1			4456
PVC		0,4 mg/ml	6掬C		14			4456
PVC		0,5 mg/ml	25掬C		3			4456
PVC		0,5 mg/ml	37掬C		2			4456
PVC		0,5 mg/ml	6掬C		14			4456
PVC		0,5 mg/ml	25掬C		3			4456
PVC		0,5 mg/ml	37掬C		1			4456
PVC		0,5 mg/ml	6掬C		14			4456
		2 mg/ml	2-8掬C		7			4922
		120 mg/ml	25掬C		12			4326
		125 mg/ml	20-25掬C		48			4634
		20 mg/ml	25掬C		48			644
		40 mg/ml	25掬C		12			4326
		125 mg/ml	20-25掬C		48			4634
		2 mg/ml	2-8掬C		7			4922
		5 & 20 mg/ml	25掬C		24			604
		5 & 20 mg/ml	4掬C		14			604
		50 mg/ml	37掬C		48			4634
		5 & 20 mg/ml	25掬C		24			604
		5 & 20 mg/ml	4掬C		14			604
		50 mg/ml	37掬C		48			4634
		100 mg/ml	37掬C		24			2042



娣峰怙鏑十 ŭ 淪氣

		8,6 mg/ml	23掙C		Ranitidine hydrochloride : 0,5 mg/ml	4		360
		8,6 mg/ml	22掙C-23掙C		Ranitidine hydrochloride : 0,5 mg/ml	4		360
		200 mg/ml	25掙C		Clindamycin phosphate : 60 mg/ml	48		644
		20 mg/ml	25掙C		Clindamycin phosphate : 9 mg/ml	48		432
		20 mg/ml	25掙C		Clindamycin phosphate : 9 mg/ml	48		432
		10 & 20 mg/ml	22掙C-23掙C		Clindamycin phosphate : 3 & 6 mg/ml	48		419
		4 mg/ml	23掙C		Vancomycin hydrochloride : 1 mg/ml	31		284
		10 & 20 mg/ml	23掙C-25掙C		Cefazolin sodium : 5 & 20 mg/ml	48		426
		10 mg/ml	24掙C		Ampicillin sodium - sulbactam sodium : 20 mg/ml	24		258
		10 & 20 mg/ml	25掙C		Gentamicin sulfate : 0,2 & 0,8 mg/ml	8		19
		10 & 20 mg/ml	25掙C		Cefoxitin sodium : 10 & 20 mg/ml	12		19
		10 & 20 mg/ml	25掙C		Tobramycin sulfate : 0,2 & 0,8 mg/ml	48		19
		4 mg/ml	32掙C		Vancomycin hydrochloride : 1 mg/ml	7		284
		10 & 20 mg/ml	4掙C		Clindamycin phosphate : 3 & 6 mg/ml	7		419
		10 & 20 mg/ml	4掙C		Tobramycin sulfate : 0,2 mg/ml	7		19
		10 & 20 mg/ml	4掙C		Tobramycin sulfate : 0,2 & 0,8 mg/ml	7		19
		10 & 20 mg/ml	4掙C		Cefoxitin sodium : 10 & 20 mg/ml	7		19
		4 mg/ml	4掙C		Vancomycin hydrochloride : 1 mg/ml	31		284
		10 & 20 mg/ml	4掙C		Gentamicin sulfate : 0,2 & 0,8 mg/ml	24		19
		10 & 20 mg/ml	4掙C-5掙C		Cefazolin sodium : 5 & 20 mg/ml	7		426
		10 mg/ml	5掙C		Ampicillin sodium - sulbactam sodium : 20 mg/ml	24		258
		10 & 20 mg/ml	22掙C-23掙C		Clindamycin phosphate : 3 & 6 mg/ml	48		419
		4 mg/ml	23掙C		Vancomycin hydrochloride : 1 mg/ml	14		284
		10 & 20 mg/ml	23掙C-25掙C		Cefazolin sodium : 5 & 20 mg/ml	48		426
		10 & 20 mg/ml	25掙C		Gentamicin sulfate : 0,2 & 0,8 mg/ml	8		19
		10 & 20 mg/ml	25掙C		Cefoxitin sodium : 10 & 20 mg/ml	12		19
		10 & 20 mg/ml	25掙C		Tobramycin sulfate : 0,2 & 0,8 mg/ml	48		19
		4 mg/ml	32掙C		Vancomycin hydrochloride : 1 mg/ml	7		284
		10 & 20 mg/ml	4掙C		Clindamycin phosphate : 3 & 6 mg/ml	7		419
		10 & 20 mg/ml	4掙C		Tobramycin sulfate : 0,2 mg/ml	7		19

PVC		10 & 20 mg/ml	4掬C		Tobramycin sulfate : 0,2 & 0,8 mg/ml	7		19
PVC		10 & 20 mg/ml	4掬C		Cefoxitin sodium : 10 & 20 mg/ml	7		19
PVC		4 mg/ml	4掬C		Vancomycin hydrochloride : 1 mg/ml	31		284
PVC		10 & 20 mg/ml	4掬C		Gentamicin sulfate : 0,2 & 0,8 mg/ml	24		19
PVC		10 & 20 mg/ml	4掬C-5掬C		Cefazolin sodium : 5 & 20 mg/ml	7		426
POF		20 mg/ml	23掬C		Linezolid : 2 mg/ml	7		1658
POF		20 mg/ml	4掬C		Linezolid : 2 mg/ml	7		1658
?		16,7 mg/ml	22掬C-28掬C	?	Daptomycin : 16,7 mg/ml	2		1937



褰卞摺绋冲晶鎢 x 殒鐢熻礈

				2263
--	--	--	--	------



鎢煎 鎢

		Aztreonam : 40 mg/ml Aciclovir sodium : 7 mg/ml	99
		Aztreonam Aciclovir sodium	3595
		Aztreonam : 40 mg/ml Allopurinol sodium : 3 mg/ml	307
		Aztreonam : 40 mg/ml Amifostine : 10 mg/ml	3
		Aztreonam Amikacin sulfate	3549
		Aztreonam : 40 mg/ml Amikacin sulfate : 5 mg/ml	99
		Aztreonam : 40 mg/ml Aminophylline : 2.5 mg/ml	99
		Aztreonam : 40 mg/ml Amphotericin B : 0.6 mg/ml	99
		Aztreonam : 40 mg/ml Amphotericin B cholesteryl sulfate complex : 0.83 mg/ml	921
		Aztreonam : 10 & 20 mg/ml Ampicillin sodium : 5 & 20 mg/ml	422
		Aztreonam : 10 & 20 mg/ml Ampicillin sodium : 5 & 20 mg/ml	422
		Aztreonam : 40 mg/ml Ampicillin sodium : 20 mg/ml	99
		Aztreonam : 40 mg/ml Ampicillin sodium - sulbactam sodium : 20/10 mg/ml	99
		Aztreonam : 40 mg/ml Amsacrine : 1 mg/ml	253

		Aztreonam : 200 mg/ml Azithromycine : 2 mg/ml		1800
		Aztreonam : 40 mg/ml Bivalirudin : 5 mg/ml		1713
		Aztreonam : 40 mg/ml Bleomycin sulfate : 1 mg/ml		99
		Aztreonam : 40 mg/ml Bumetanide : 0.04 mg/ml		99
		Aztreonam : 40 mg/ml Buprenorphine hydrochloride : 0.04 mg/ml		99
		Aztreonam : 40 mg/ml Butorphanol tartrate : 0.04 mg/ml		99
		Aztreonam : 40 mg/ml Calcium gluconate : 40 mg/ml		99
		Aztreonam : 40 mg/ml Carboplatin : 5 mg/ml		99
		Aztreonam : 40 mg/ml Carmustine : 1.5 mg/ml		99
		Aztreonam : 40 mg/ml Caspofungin acetate : 0,7 mg/ml		2247
		Aztreonam : 20 mg/ml Caspofungin acetate : 0.5 mg/ml		2233
		Aztreonam : 40 mg/ml Cefazolin sodium : 20 mg/ml		99
		Aztreonam : 10 & 20 mg/ml Cefazolin sodium : 5 & 20 mg/ml		426
		Aztreonam : 10 & 20 mg/ml Cefazolin sodium : 5 & 20 mg/ml		426
		Aztreonam : 20 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Aztreonam : 20 mg/ml Cefiderocol sulfate tosylate : 20 mg/mL		4528
		Aztreonam : 40 mg/ml Cefonicid sodium : 20 mg/ml		99
		Aztreonam : 40 mg/ml Cefoperazone sodium : 40 mg/ml		99
		Aztreonam : 40 mg/ml Cefotaxime sodium : 20 mg/ml		99
		Aztreonam : 10 & 20 mg/ml Cefoxitin sodium : 10 & 20 mg/ml		19
		Aztreonam : 40 mg/ml Cefoxitin sodium : 20 mg/ml		99
		Aztreonam : 10 & 20 mg/ml Cefoxitin sodium : 10 & 20 mg/ml		19
		Aztreonam : 40 mg/ml Ceftazidime : 40 mg/ml		99
		Aztreonam : 10 & 20 mg/ml Ceftazidime Avibactam : 8,25 & 50 mg/ml		4548
		Aztreonam : 40 mg/ml Ceftizoxime sodium : 20 mg/ml		99
		Aztreonam : 20 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828

		Aztreonam : 20 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
		Aztreonam : 40 mg/ml Ceftriaxone disodium : 20 mg/ml		99
		Aztreonam : 40 mg/ml Cefuroxime sodium : 30 mg/ml		99
		Aztreonam : 40 mg/ml Chlormethine hydrochloride : 1 mg/ml		99
		Aztreonam : 40 mg/ml Chlorpromazine hydrochloride : 2 mg/ml		99
		Aztreonam : 40 mg/ml Cimetidine hydrochloride : 12 mg/ml		99
		Aztreonam : 20 mg/ml Ciprofloxacin lactate : 1 mg/ml		500
		Aztreonam : 20 mg/ml Ciprofloxacin lactate : 1 mg/ml		500
		Aztreonam : 40 mg/ml Ciprofloxacin lactate : 2 mg/ml		285
		Aztreonam : 40 mg/ml Ciprofloxacin lactate : 1 mg/ml		99
		Aztreonam : 40 mg/ml Cisatracurium besylate : 0.1 >> 5 mg/ml		299
		Aztreonam : 40 mg/ml Cisplatin : 1 mg/ml		99
		Aztreonam : 20 mg/ml Clindamycin phosphate : 9 mg/ml		432
		Aztreonam Clindamycin phosphate		3526
		Aztreonam : 10 mg/ml Clindamycin phosphate : 6 mg/ml		419
		Aztreonam : 10 mg/ml Clindamycin phosphate : 3 mg/ml		419
		Aztreonam : 40 mg/ml Clindamycin phosphate : 10 mg/ml		99
		Aztreonam : 20 mg/ml Clindamycin phosphate : 3 mg/ml		419
		Aztreonam : 20 mg/ml Clindamycin phosphate : 6 mg/ml		419
		Aztreonam : 20 mg/ml Clindamycin phosphate : 6 mg/ml		419
		Aztreonam : 20 mg/ml Clindamycin phosphate : 3 mg/ml		419
		Aztreonam : 10 mg/ml Clindamycin phosphate : 3 mg/ml		419
		Aztreonam : 20 mg/ml Clindamycin phosphate : 9 mg/ml		432
		Aztreonam Clindamycin phosphate		3526
		Aztreonam : 200 mg/ml Clindamycin phosphate : 60 mg/ml		644
		Aztreonam : 10 mg/ml Clindamycin phosphate : 6 mg/ml		419

		Aztreonam : 40 mg/ml Co-trimoxazole : 4/0.8 mg/ml		99
		Aztreonam : 40 mg/ml Cyclophosphamide : 10 mg/ml		99
		Aztreonam : 40 mg/ml Cytarabine : 50 mg/ml		99
		Aztreonam : 40 mg/ml Dacarbazine : 4 mg/ml		99
		Aztreonam : 40 mg/ml Dactinomycin : 10 碌g/ml		99
		Aztreonam Daptomycin		2271
		Aztreonam : 16,7 mg/ml Daptomycin : 16,7 mg/ml		1937
		Aztreonam : 40 mg/ml Daunorubicin hydrochloride : 1 mg/ml		99
		Aztreonam : 40 mg/ml Dexamethasone sodium phosphate : 1 mg/ml		99
		Aztreonam : 40 mg/ml Dexmedetomidine : 4 碌g/ml		1712
		Aztreonam : 333 mg/ml Diltiazem hydrochloride : 1 mg/ml		198
		Aztreonam : 20 & 333 mg/ml Diltiazem hydrochloride : 5 mg/ml		198
		Aztreonam : 40 mg/ml Diphenhydramine hydrochloride : 2 mg/ml		99
		Aztreonam : 40 mg/ml Dobutamine hydrochloride : 4 mg/ml		99
		Aztreonam : 40 mg/ml Docetaxel : 0.9 mg/ml		1754
		Aztreonam : 40 mg/ml Dopamine hydrochloride : 3.2 mg/ml		99
		Aztreonam : 40 mg/ml Doxorubicin hydrochloride : 2 mg/ml		99
		Aztreonam : 40 mg/ml Doxorubicin hydrochloride liposome peg : 0.4 mg/ml		251
		Aztreonam : 40 mg/ml Doxycycline hyclate : 1 mg/ml		99
		Aztreonam : 40 mg/ml Droperidol : 0.4 mg/ml		99
		Aztreonam : 40 mg/ml Enalaprilate : 0.1 mg/ml		99
		Aztreonam : 10 mg/ml Enalaprilate : 0.05 mg/ml		1315
		Aztreonam : 40 mg/ml Fenoldopam mesylate : 80 碌g/ml		1803
		Aztreonam		3547
		Aztreonam : 40 mg/ml		301
		Aztreonam Erythromycin lactobionate		3674
		Aztreonam : 40 mg/ml		1415

	Aztreonam : 20 mg/ml Eravacycline : 0,6 mg/ml		4434
	Aztreonam : 40 mg/ml Etoposide : 0.4 mg/ml		99
	Aztreonam : 40 mg/ml Etoposide phosphate : 5 mg/ml		1410
	Aztreonam : 40 mg/ml Famotidine : 2 mg/ml		99
	Aztreonam : 40 mg/ml Filgrastim : 30 碌g/ml		244
	Aztreonam : 40 mg/ml Floxadine : 3 mg/ml		99
	Aztreonam : 40 mg/ml Fluconazole : 2 mg/ml		99
	Aztreonam : 40 mg/ml Fluconazole : 2 mg/ml		496
	Aztreonam		3547
	Aztreonam : 40 mg/ml Filgrastim : 30 碌g/ml		99
	Aztreonam : 40 mg/ml Fludarabine phosphate : 1 mg/ml		492
	Aztreonam : 40 mg/ml Fludarabine phosphate : 1 mg/ml		99
	Aztreonam : 40 mg/ml Fluorouracil : 16 mg/ml		99
	Aztreonam : 40 mg/ml Folate calcium : 2 mg/ml		99
	Aztreonam : 40 mg/ml Foscarnet sodium : 24 mg/ml		1135
	Aztreonam : 40 mg/ml Foscarnet sodium : 24 mg/ml		1135
	Aztreonam : 40 mg/ml Foscarnet sodium : 24 mg/ml		73
	Aztreonam : 20 mg/ml Fosfomycin : 30 mg/ml		4055
	Aztreonam : 20 mg/ml Fosfomycin : 30 mg/ml		4055
	Aztreonam : 40 mg/ml Furosemide : 3 mg/ml		99
	Aztreonam : 40 mg/ml Gallium nitrate : 0.4 mg/ml		99
	Aztreonam : 40 mg/ml Ganciclovir sodium : 20 mg/ml		99
	Aztreonam : 40 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
	Aztreonam : 40 mg/ml Heparin sodium : 100 UI/ml		99
	Aztreonam		3547
	Aztreonam : 10 & 20 mg/ml Gentamicin sulfate : 0.2 & 0.8 mg/ml		19
	Aztreonam : 10 & 20 mg/ml Gentamicin sulfate : 0.2 & 0.8 mg/ml		19

	Aztreonam : 40 mg/ml Gentamicin sulfate : 5 mg/ml		99
	Aztreonam : 40 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
	Aztreonam : 40 mg/ml Haloperidol lactate : 0.2 mg/ml		99
	Aztreonam : 20 mg/ml Heparin sodium : 50 UI/ml		317
	Aztreonam : 40 mg/ml Hetastarch : 60 mg/ml		1721
	Aztreonam : 40 mg/ml Hydrocortisone sodium succinate : 1 mg/ml		99
	Aztreonam : 40 mg/ml Hydromorphone hydrochloride : 0.5 mg/ml		99
	Aztreonam : 40 mg/ml Hydroxyzine dihydrochloride : 4 mg/ml		99
	Aztreonam : 40 mg/ml Idarubicin hydrochloride : 0.5 mg/ml		99
	Aztreonam : 40 mg/ml Ifosfamide : 25 mg/ml		99
	Aztreonam : 40 mg/ml Imipenem - cilastatin sodium : 10 mg/ml		99
	Aztreonam : 20 mg/ml Insulin : 0.2 UI/ml		129
	Aztreonam : 20 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
	Aztreonam : 20 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
	Aztreonam : 40 mg/ml Lansoprazole : 0.55 mg/ml		1625
	Aztreonam : 40 mg/ml Linezolid : 2 mg/ml		1925
	Aztreonam : 20 mg/ml Linezolid : 2 mg/ml		1658
	Aztreonam : 40 mg/ml Lorazepam : 0.1 mg/ml		99
	Aztreonam : 40 mg/ml Magnesium sulfate : 100 mg/ml		99
	Aztreonam : 40 mg/ml Mannitol : 0.15 mg/ml		99
	Aztreonam : 40 mg/ml Melfalan : 0.1 mg/ml		169
	Aztreonam : 100 mg/ml Meropenem : 50 mg/ml		4389
	Aztreonam : 100 mg/ml Meropenem : 50 mg/ml		4319
	Aztreonam : 40 mg/ml Mesna : 10 mg/ml		99
	Aztreonam : 40 mg/ml Methotrexate sodium : 15 mg/ml		99
	Aztreonam : 40 mg/ml Methylprednisolone sodium succinate : 5 mg/ml		99

		Aztreonam : 40 mg/ml Metoclopramide hydrochloride : 5 mg/ml		99
		Aztreonam : 40 mg/ml Metronidazole : 5 mg/ml		99
		Aztreonam Metronidazole		3547
		Aztreonam : 10 & 20 mg/ml Metronidazole : 5 mg/ml		19
		Aztreonam : 40 mg/ml Minocycline hydrochloride : 0.2 mg/ml		99
		Aztreonam : 40 mg/ml Mitomycin : 0.5 mg/ml		99
		Aztreonam : 40 mg/ml Mitoxantrone dihydrochloride : 0.5 mg/ml		99
		Aztreonam : 20 mg/ml Morphine sulfate : 1 mg/ml		62
		Aztreonam : 40 mg/ml Morphine sulfate : 1 mg/ml		99
		Aztreonam Nafcillin sodium		3547
		Aztreonam : 10 >> 20 mg/ml Nafcillin sodium : 10 >> 20 mg/ml		433
		Aztreonam : 10 >> 20 mg/ml Nafcillin sodium : 10 >> 20 mg/ml		433
		Aztreonam : 40 mg/ml Nalbuphine hydrochloride : 10 mg/ml		99
		Aztreonam : 40 mg/ml Netilmicin sulfate : 5 mg/ml		99
		Aztreonam : 10 mg/ml Nicardipine hydrochloride : 0.1 mg/ml		1490
		Aztreonam : 10 mg/ml Nicardipine hydrochloride : 0.1 mg/ml		1490
		Aztreonam : 40 mg/ml Ondansetron hydrochloride : 1 mg/ml		334
		Aztreonam : 40 mg/ml Ondansetron hydrochloride : 1 mg/ml		99
		Aztreonam : 20 mg/ml Oritavancin : 0.8 >> 2 mg/ml		3152
		Aztreonam : 40 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Aztreonam : 40 mg/ml Pethidine hydrochloride : 4 mg/ml		99
		Aztreonam : 20 mg/ml Pethidine hydrochloride : 10 mg/ml		62
		Aztreonam : 40 mg/ml Phloroglucinol : 2,5 mg/ml		3791
		Aztreonam : 40 mg/ml Piperacillin sodium : 40 mg/ml		99
		Aztreonam : 40 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
		Aztreonam : 20 mg/ml Plazomicin sulfate : 24 mg/ml		4145

		Aztreonam : 40 mg/ml Potassium chloride : 100 mEq/l		99
		Aztreonam : 40 mg/ml Prochlorperazine edysilate : 0.5 mg/ml		99
		Aztreonam : 40 mg/ml Promethazine hydrochloride : 2 mg/ml		99
		Aztreonam : 40 mg/ml Propofol : 10 mg/ml		300
		Aztreonam : 20 mg/ml Quinupristine/dalfopristine : 2 mg/ml		1513
		Aztreonam : 40 mg/ml Ranitidine hydrochloride : 2 mg/ml		99
		Aztreonam : 40 mg/ml Remifentanil hydrochloride : 25 & 250 碌g/ml		59
		Aztreonam : 40 mg/ml Sargramostim : 10 碌g/ml		99
		Aztreonam : 40 mg/ml Sargramostim : 10 碌g/ml		335
		Aztreonam : 40 mg/ml Sodium bicarbonate : 84 mg/ml		99
		Aztreonam : 40 mg/ml Streptozocin : 40 mg/ml		99
		Aztreonam : 20 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
		Aztreonam : 20 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
		Aztreonam : 40 mg/ml Teniposide : 0.1 mg/ml		99
		Aztreonam : 40 mg/ml Teniposide : 0.1 mg/ml		905
		Aztreonam : 20 mg/ml Theophylline : 4 mg/ml		317
		Aztreonam : 40 mg/ml Thiotepa : 1 mg/ml		249
		Aztreonam : 40 mg/ml Ticarcillin / clavulanic acid : 30 mg/ml		99
		Aztreonam : 40 mg/ml Vancomycin hydrochloride : 10 mg/ml		284
		Aztreonam		3547
		Aztreonam : 40 mg/ml Thiotepa : 1 mg/ml		99
		Aztreonam : 10 & 20 mg/ml Tobramycin sulfate : 0.2 & 0.8 mg/ml		19
		Aztreonam : 10 & 20 mg/ml Tobramycin sulfate : 0.2 & 0.8 mg/ml		19
		Aztreonam : 40 mg/ml Tobramycin sulfate : 5 mg/ml		99
		Aztreonam : 40 mg/ml Vancomycin hydrochloride : 10 mg/ml		284
		Aztreonam : 4 mg/ml Vancomycin hydrochloride : 1 mg/ml		284

	Aztreonam : 4 mg/ml Vancomycin hydrochloride : 1 mg/ml		284
 	Aztreonam : 200 mg/ml Vancomycin hydrochloride : 66.67 mg/ml		94
	Aztreonam : 40 mg/ml Vancomycin hydrochloride : 10 mg/ml		99
	Aztreonam : 40 mg/ml Vinblastine sulfate : 0.12 mg/ml		99
	Aztreonam : 40 mg/ml Vincristine sulfate : 0.05 mg/ml		99
	Aztreonam : 40 mg/ml Vinorelbine tartrate : 1 mg/ml		84
	Aztreonam : 40 mg/ml Zidovudine : 4 mg/ml		99
	Aztreonam : 40 mg/ml Zidovudine : 4 mg/ml		337



鑿 × 嶺閩旂緞



寮曡鍩錐囩奈

	纒嶇被	鍍虹增鍓
3	錐囩奈	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
19	錐囩奈	Bell RG, Lipford LC, Massanari MJ, Riley CM. Stability of intravenous admixtures of aztreonam and ceftiofur, gentamicin, metronidazole, or tobramycin. Am J Hosp Pharm 1986 ; 43: 1444-1453.
59	錐囩奈	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
62	錐囩奈	Pugh CB, Pabis DJ, Rodriguez C. Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 123-125.
73	錐囩奈	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
81	錐囩奈	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	錐囩奈	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.

94	鑑図奈	Chandler SW, Folstad J, Trissel LA. Aztreonam-vancomycin incompatibility. Am J Hosp Pharm 1990 ; 47: 1970.
99	鑑図奈	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
129	鑑図奈	Smythe M, Malouf E. Visual compatibility of insulin with secondary intravenous drugs in admixtures. Am J Hosp Pharm 1991 ; 48: 125-126.
169	鑑図奈	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	鑑図奈	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
198	鑑図奈	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
244	鑑図奈	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	鑑図奈	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251	鑑図奈	Trissel LA, Gilbert DL, Martinez JF. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
253	鑑図奈	Trissel LA, Chandler SW, Folstad JT. Visual compatibility of amsacrine with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 2525-2528.
258	鑑図奈	Belliveau PP, Nightingale CH, Quintiliani R. Stability of aztreonam and ampicillin sodium-sulbactam sodium in 0.9% sodium chloride injection. Am J Hosp Pharm 1994 ; 51: 901-904.
284	鑑図奈	Trissel LA, Xu QA, Martinez JF. Compatibility and stability of aztreonam and vancomycin hydrochloride. Am J Health-Syst Pharm 1995 ; 52: 2560-2564.
285	鑑図奈	Elmore RL, Contois ME, Kelly J, Noe A, Poirier A. Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs. Clin Ther 1996 ; 18: 246-255.
299	鑑図奈	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	鑑図奈	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	鑑図奈	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	鑑図奈	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.

317	鑑固奈	Kershaw BP, Monnier HL, Mason JH. Visual compatibility of premixed theophylline or heparin with selected drugs for IV administration. Am J Hosp Pharm 1993 ; 50: 1360-1362.
334	鑑固奈	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	鑑固奈	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
337	鑑固奈	Bashaw ED, Amantea MA, Minor JR, Galleli JF. Visual compatibility of zidovudine with other drugs during simulated Y-site administration. Am J Hosp Pharm 1988 ; 45: 2532-2533.
360	鑑固奈	Inagaki K, Gill MA, Okamoto MP, Takagi J. Stability of ranitidine hydrochloride with aztreonam, ceftazidime, or piperacillin sodium during simulated Y-site administration. Am J Hosp Pharm 1992 ; 49: 2769-2772.
419	鑑固奈	James MJ, Riley CM. Stability of intravenous admixtures of aztreonam and clindamycin phosphate. Am J Hosp Pharm 1985 ; 42: 1984-1986.
422	鑑固奈	James MJ, Riley CM. Stability of intravenous admixtures of aztreonam and ampicillin. Am J Hosp Pharm 1985 ; 42: 1095-1100.
426	鑑固奈	Riley CM, James MJ. Stability of intravenous admixtures containing aztreonam and cefazolin. Am J Hosp Pharm 1986 ; 43: 925-927.
432	鑑固奈	Marble DA, Bosso JA, Townsend RJ. Stability of clindamycin phosphate with aztreonam, ceftazidime sodium, ceftriaxone sodium, or piperacillin sodium in two intravenous solutions. Am J Hosp Pharm 1986 ; 43: 1732-1736.
433	鑑固奈	Riley CM, Lipford LC. Interaction of aztreonam with nafcillin in intravenous admixtures. Am J Hosp Pharm 1986 ; 43: 2221-2224.
492	鑑固奈	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
496	鑑固奈	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
500	鑑固奈	Tucker DR, Sieradzan R. Visual compatibility of ciprofloxacin lactate with five broad-spectrum antimicrobial agents during simulated Y-site injection. Am J Hosp Pharm 1988 ; 45: 1910-1911.
604	淪為撇淪	Stabilit茅 des m茅dicaments dans l'Intermate 芦 SV50, 100, 200 Baxter 1998
644	鑑固奈	Marble DA, Bosso JA, Townsend RJ. Compatibility of clindamycin phosphate with aztreonam in polypropylene syringes and with cefoperazone sodium, cefonicid sodium, and cefuroxime sodium in partial-fill glass bottles. Drug Intell Clin Pharm 1988 ; 22: 54-57.
905	鑑固奈	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.

921	鑑因奈	Trissel LA, Gilbert DL, Martinez JF. Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs during simulated Y-site administration. Hosp Pharm 1998 ; 33: 284-292.
1064	鑑因奈	Vinks AATMM, Touw DJ, van Rossen RCJM, Heijeiman HGM, Bakker W. Stability of aztreonam in a portable pump reservoir used for home intravenous antibiotic treatment (HIVAT). Pharm World Sci 1996 ; 18: 74-77.
1135	鑑因奈	Baltz JK, Kennedy P, Minor JR, Gallelli J. Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1990 ; 47: 2075-2077.
1233	鑑因奈	McLaughlin JP, Simpson C. The stability of reconstituted aztreonam. Br J Pharm Pract 1990 ; 12: 328, 330, 334.
1315	鑑因奈	Halpern NA, Colucci RD, Alicea M, Greenstein R. Visual compatibility of enalaprilat with commonly used critical care medications during simulated Y-site injection. Int J Pharm Clin Pharmacol Ther Tox 1989 ; 27: 294-297.
1410	鑑因奈	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	鑑因奈	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	鑑因奈	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1490	鑑因奈	Halpern NA, Colucci RD, Alicea M, Greenstein R. The compatibility of nicardipine hydrochloride injection with various ICU medications during simulated Y-site injection.
1513	論為撇論	Quinipristin Dihydrochloride (Syn 411) 第4版 Monarch Pharmaceuticals Ireland 2006
1625	鑑因奈	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1658	鑑因奈	Zhang Y, Xu QA, Trissel LA, Willimas KY. Compatibility and stability of linezolid injection admixed with aztreonam or piperacillin sodium. J Am Pharm Assoc 2000 ; 40: 520-524.
1712	鑑因奈	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	鑑因奈	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	鑑因奈	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	鑑因奈	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.
1800	鑑因奈	Voytilla KL, Tyler LS, Rusho WJ. Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery. Am J Health-Syst Pharm 2002 ; 59: 853-855.

1803	鑑固奈	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1925	鑑固奈	Trissel LA , Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1937	鑑固奈	Lai JJ, Brodeur SK. Physical and chemical stability of daptomycin with nine medications. Ann Pharmacotherapy 2004 ; 38: 1612-1616.
1953	鑑固奈	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
2042	鑑固奈	Viaene E, Chanteux H, Servais H, Mingeot-Leclercq MP, Tulkens PM. Comparative stability studies of antipseudomonal 脰-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother 2002 ; 46: 2327-2332.
2233	鑑固奈	Condie C.K, Tyler L.S, Barker B, Canann D.M. Visual compatibility of caspofungin acetate with commonly used drugs during simulated Y-site delivery Am J Health-Syst Pharm 2008 ; 65, 5: 454-457.
2247	鑑固奈	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
2263	鑑固奈	Zajac M, Jelinska A, Cielecka-Piontek J, Osqczapowicz I. Stability of aztreonam in AZACTAM. Il Farmaco 2005 ; 60: 599-603.
2271	淪為獺淪	Daptomycine (Cubicin) R茅sum茅 des caract茅ristiques du produits Novartis 2006
3152	鑑固奈	Kumar A, Mann HJ. Visual compatibility of oritavancin diphosphate with selected coadministered drugs during simulated Y-site administration. Am J Health-Syst Pharm 2010 ; 67: 1640-1644.
3526	淪為獺淪	Clindamycin (Dalacin) - Summary of Product Characteristics Pharmacia 2010
3547	淪為獺淪	Aztr茅onam (Azactam) - R茅sum茅 des caract茅ristiques du produit Sanofi-Aventis France 2011
3549	淪為獺淪	Amikacine B Braun - R茅sum茅 des caract茅ristiques du produit. B Braun 2012
3595	淪為獺淪	Aciclovir - Summary of Product Characteristics Hospira 2009
3674	淪為獺淪	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3791	姻鋒妬	Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P. 脧tude de la compatibilit茅 physico-chimique du phloroglucinol injectable durant les m茅langes au sein des tubulures en Y. Apifh Congress, Paris November 2014 2014
3827	姻鋒妬	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	姻鋒妬	Thabit A.K, Hamada Y, Nicolau D.P. Ceftazolin/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015



瀛梔吁

	鐳梔攸綽		娉厶催娑
	鐳喲搨錫		婧舵恫緋冲晶鎬
	淪瑰榛		錄喲璫
	嫻攸害		媿十害
	淇漬珥		紂十晶鏤佺笱鏽�佺
	鑿熒澤浹胯＝鉸		鏹浣混鑽勳際鐙
	寮�敳鑑囡奈		鑿葦拊
	娉厶催鑿厶按		閭垮厓
	鐳藉お		NaCl 0,9%
	鐙		灑忔祿
	鐳 厶 佺緋 %		NaCl 0.9% + 鐙 厶 0.4%
	鐳氣隘涔攢儻		鐳攸璫變嫻 佺
	Extraneal厶 (Baxter)		Nutrineal厶
	Physion茅al厶 1.36 (Baxter)		Physion茅al厶 2.27 (Baxter)
	娉厶催鐙 鐳�箇鐙		鐳�煦鋤婁笱鐙 練鎬 厶 玲
	褰塚 厶 玲鐙塚酒鏤囧晶鐙		娉峰怙鐳十 ũ 淪氣
	婧蹂璫		錄喲璫
	涓蔭		鐳�儻鐙
	鐳		褰卞摨緋冲晶鎬 x 殒鏹攸礪
	澧烱姑		璇卞
	錄鳴 B		鐙煎 鎬
	垮嬪嵒婁爰頰		涓嶳淝淪
	鏈 f 害淪氬殒涓嶳吋淪規		鐙煎
	鏈棧 涓嶳---淪氣		垮嬪嵒媿炬綻
	鐳 厶 佺緋 0%		鐳豺 鐳 厶 吁鐙堅笱纈槽販錫堅澤鐙
	鐳豺 鐳 厶 吁鐙堅慳鐳傷楓鐙		NaCl 0.45%
	鐳瑰晶婧舵恫		涓 灑�櫀媿炬綻
	4灑�櫀褰爰畛鐳		12灑�櫀褰爰畛鐳
	1灑�櫀褰爰屾漣鐳		6灑�櫀褰爰屾漣鐳
	4灑�櫀鐙 厶 妇婢		1灑�櫀褰爰畛鐳

	璽×律閭旂綴		闡樂劊娉∟唯
	闡樂劊杈檄恫		鑲岵軌鏐
	寮曠戔鑑囡奈		瀛楮吁